TARGET
saveCD20
B-cell antigen; target of rituximab and obinutuzumab.
also known as: ms4a1, b-lymphocyte antigen cd20
🐶 often sniffed alongside
top 8- tagRecall3 co-mentions · 3 sources
- tagOncology3 co-mentions · 1 sources
- tagMonoclonal Antibody3 co-mentions · 3 sources
- tagCLL2 co-mentions · 1 sources
- tagCD191 co-mentions · 1 sources
- tagDLBCL1 co-mentions · 1 sources
- tagCD221 co-mentions · 1 sources
- drugAnti-CD19/CD20/CD22 CAR T-cells1 co-mentions · 1 sources
drugs
0
catalysts
0
news
12
companies
0
Top drugs
no drugs tagged with this interest yet
🐶 Top companies
no companies tagged with this interest yet
Recent catalysts
no catalysts tagged with this interest yet
Recent news
view all →- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750Mbiospace · 19d ago
- The hidden scale-out problem behind CAR-T’s growthbiopharma dive · 1mo ago
- Roche finds another oncology gem in Asia with $1.5B B cell disease partnershipbiospace · 1mo ago
- Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyfiercebiotech · 1mo ago
- After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?fiercebiotech · 1mo ago
- Legend Biotech CEO abruptly steps down without permanent replacementfiercebiotech · 2mo ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace · 2mo ago
- Legend surges on early data for ‘in vivo’ lymphoma cell therapybiopharma dive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that